Tivozanib
Advanced Sarcomatoid Renal Cell Carcinoma
City of Hope Medical CenterSmall moleculePhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Advanced Sarcomatoid Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab City of Hope Medical Center | Phase 3 | BB |
Bms-907351 City of Hope Medical Center | Phase 3 | BB |
Ipilimumab City of Hope Medical Center | Phase 3 | BB |
gw786034 Mayo Clinic | Phase 2 | B |
View all 18 →
Same molecule, other indications
Tivozanib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →